Biologics Coverage

Monoclonal Antibodies (Mabs) Market Definition And Segments

Monoclonal antibodies (MABS) refer to laboratory-produced proteins intended to boost your immune system. Treatments for monoclonal antibodies are often administered as IV solutions, frequently in an infusion center. Antibodies are a component of your immune system. To kill them, they seek out the antigens (foreign substances) and adhere to them. The main types of sources of monoclonal antibodies (MABS) are murine, chimeric, humanized, and human. A murine antibody has two types of chains, one of which is from a mouse and the other from a human. The pre-stem -o- in the INN of a murine antibody is used to identify it. It is used in anti-cancer, immunological, anti-infective monoclonal antibodies (MAbs), neuropharmacological, cardiovascular, cerebrovascular, and other applications and is implemented in various sectors such as hospitals, private clinics, and research institutes. The monoclonal antibodies (MAbs) market covered in this report is segmented – 1) By Source: Murine, Chimeric, Humanized, Human 2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications 3) By End Users: Hospitals, Private Clinics, Research Institute The monoclonal antibodies (mabs) market size has grown rapidly in recent years. It will grow from $234.37 billion in 2023 to $261.66 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to prevalence of chronic diseases, increasing investment in R&D, growing awareness of mabs, growing elderly population. The monoclonal antibodies (mabs) market size is expected to see rapidly grown in the next few years. It will grow to $424.24 billion in 2028 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to expanding therapeutic indications, personalized medicine, biosimilars and generics, combination therapies, pandemic preparedness, biopharmaceutical investment. Major trends in the forecast period include immunotherapy advancements, subcutaneous administration, next-generation antibodies, subcutaneous formulations, digital health integration, advancements in biotechnology.

Rising Popularity Of Cost-Efficient Biosimilar Monoclonal Antibodies Fuels Monoclonal Antibody Market Growth

The increasing prevalence of cost-efficient biosimilar monoclonal antibodies is driving the monoclonal antibody market's growth. The biosimilars' aim is to curb the increasing cost of healthcare and handle economic pressure from the patient pod and governments to reduce the cost of medication and increase access to treatment. Biosimilars are pharmaceuticals that are developed to have similar properties to a biological drug that has already been approved. A biosimilar monoclonal antibody costs 20%–25% less than the original biologic drug. The number of clinical trials for a biosimilar is comparatively smaller than that of the original biologic drug, and this proves to be the reason for the low cost of a biosimilar drug. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilar drugs industry.

Chronic Disease Prevalence Driving Growth In The Monoclonal Antibodies (MABS) Market

The increasing prevalence of chronic diseases is expected to propel the growth of the monoclonal antibodies (mAbs) market going forward. Chronic diseases are long-lasting conditions that usually cannot be cured but can be managed with proper medical attention and lifestyle changes. Monoclonal antibodies (mAbs) have been employed in the treatment of various chronic diseases, particularly those characterized by dysregulated immune responses, excessive inflammation, and specific molecular targets. For instance, in September 2023, according to the World Health Organization, noncommunicable diseases (NCDs) or chronic diseases kill 41 million people each year, equivalent to 74% of all deaths globally. Annually, 17 million individuals experience premature deaths due to non-communicable diseases (NCDs) also known as chronic diseases, before reaching the age of 70. A significant majority, specifically 86% of these early fatalities, take place in low- and middle-income countries. Therefore, the ongoing rise in the incidence of chronic diseases will persist in propelling the expansion of the monoclonal antibodies (mAbs) market. Major companies operating in the monoclonal antibodies (MABS) market include Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Amgen Inc., Novartis International AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Sanofi S.A., Abbott Laboratories, Mylan N.V., Novo Nordisk A/S, Daiichi Sankyo Company Ltd., Seattle Genetics Inc., Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Inc., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Biopharma Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd., Piramal Enterprises Ltd., Troikaa Pharmaceuticals Ltd., CD BioSciences Inc., Kanto Corporation, Molecular Depot LLC, Epigentek Group Inc., Creative Biolabs Inc., Advanced ChemTech Inc., Diagnostic BioSystems Inc., Tonbo Biosciences Inc., Abraxis LLC, GlaxoSmithKline plc

Growth Of Alternative And Natural Therapies Challenges Monoclonal Antibody Drug Market

Alternative treatment methods and natural remedies are increasingly popular globally, and this is expected to hurt the revenues of the monoclonal antibody drugs market. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, and sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, the revenue from US retail sales of homeopathic and herbal remedies was around $7.5 billion. These less expensive alternatives increase the competitiveness of the biologics market, putting downward pressure on prices and limiting the demand for monoclonal antibody drugs.

Strategic Expansion And Collaborative Initiatives Shaping The Monoclonal Antibody Market

The monoclonal antibody market has been witnessing multiple strategic initiatives in recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden their products and services. Strategic collaborations, acquisitions, and partnership agreements help vendors expand their existing product portfolio and geographical reach. For instance, in March 2022, Sanofi S.A., a France-based pharmaceutical and healthcare company specializing in the discovery, development, manufacturing, and commercialization of drugs, announced a strategic collaboration with Seagen Inc., a US-based pharmaceutical company specializing in the development and commercialization of novel, powerful monoclonal antibody-based cancer treatments. Under this agreement, the partnership will use Seagen's and Sanofi's exclusive monoclonal antibody (mAb) and antibody-drug conjugate (ADC) technologies to design, develop, and market ADCs for up to three cancer targets. Furthermore, Boehringer Ingelheim, a Germany-based research-driven pharmaceutical company, announced a collaboration with MabGenesis, Inc., a Japan-based biopharmaceutical company pioneering the development of therapeutic monoclonal antibody drugs for the treatment of human diseases. Through this collaboration, Boehringer Ingelheim and MabGenesis discovered and developed novel therapeutic monoclonal antibodies for the treatment of various diseases and strategic research and development strategies. Companies in the industry are increasingly realigning their portfolios and pursuing profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favorable interest rates globally.

Innovative Technologies To Enhance Competitiveness In The Monoclonal Antibodies Market

Major companies operating in the monoclonal antibodies market are introducing innovative technologies such as RenMice to gain a competitive edge in the market. RenMice offers strong assistance in the exploration of various antibody-based therapies, including fully human monoclonal antibodies, bispecific antibodies, bispecific antibody-drug conjugates (BsADCs), nanobodies, fully human T-cell receptors (TCRs), and TCR-mimic antibodies. For instance, in September 2023, Biocytogen Pharmaceuticals, a China-based international biotech company that drives the research and development of new drugs with innovative technologies launched the RenMice series, encompassing a selection of independently created fully human antibody mice and TCR mice, all of which possess proprietary intellectual property.

FDA's Regulatory Support And Accelerated Approvals Bolstering The Monoclonal Antibody Therapeutics Market

The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services, in the USA, regulating the monoclonal antibody and pharmaceutical drug markets. Increasing product launches and regulatory support for the treatment of rare diseases by the USFDA are expected to support the monoclonal antibody therapeutics market's growth. For instance, the U.S. The Food and Drug Administration (FDA) granted accelerated approval to avelumab (BAVENCIO, EMD Serono, Inc.), a human monoclonal antibody, for the treatment of a rare disease, metastatic Merkel cell carcinoma (MCC). Similarly, the U.S. FDA granted accelerated approval to the immunotherapy product TECENTRIQ (atezolizumab), a humanized, engineered monoclonal antibody, for the treatment of people with locally advanced or metastatic urothelial carcinoma (MUC). North America was the largest region in the monoclonal antibodies (MAbS) market in 2023. The regions covered in the monoclonal antibodies (MABS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the monoclonal antibodies (MABS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The monoclonal antibodies (MABS) market consists of sales of rituximab, cetuximab, and trastuzumab. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The monoclonal antibodies (MABS) market research report is one of a series of new reports from The Business Research Company that provides monoclonal antibodies (MABS) market statistics, such as industry global market size, regional shares, competitors with a monoclonal antibodies (MABS) market share, detailed monoclonal antibodies (MABS) market segments, market trends and opportunities, and any additional data you may require to thrive in the monoclonal antibodies (MABS) industry. This monoclonal antibody (MABS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Therapeutic Proteins Market Definition And Segments

Therapeutic proteins refer to pharmaceuticals that are genetically modified versions of human proteins that are found naturally. These powerful, quick-acting medications were developed in a lab for pharmaceutical usage. Therapeutic proteins have altered how diseases are treated since they are very effective in vivo. The main types of products in therapeutic proteins market are insulin, fusion proteins, erythropoietin, interferon, human growth hormone, and follicle-stimulating hormone. Insulin is a peptide hormone produced by beta cells in the pancreatic cells that serves as the individual's primary anabolic hormone. It affects fat, carbohydrate, and protein metabolism by boosting glucose uptake from the blood into the fat, liver, and skeletal muscle cells. The different functions include enzymatic and regulatory activity, special targeting activity, vaccines, and protein diagnostics and are used in various applications such as metabolic disorders, immunologic disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, and others. The therapeutic proteins market covered in this report is segmented – 1) By Product Type: Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone 2) By Function: Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics 3) By Application: Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications The therapeutic proteins market size has grown rapidly in recent years. It will grow from $140.96 billion in 2023 to $158.16 billion in 2024 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to advances in protein engineering, expansion into chronic diseases, advent of immunotherapy, development of recombinant DNA technology, targeted cancer therapies. The therapeutic proteins market size is expected to see rapid growth in the next few years. It will grow to $257.4 billion in 2028 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to regulatory adaptations, enhanced delivery systems, gene editing integration, biobetters development, immunotherapy evolution. Major trends in the forecast period include regulatory framework enhancements, improved delivery systems, biotechnology advancements, personalized medicine, monoclonal antibodies dominance.

Technological Advancements Fueling The Growth Of The Therapeutic Proteins Market

The therapeutic proteins market is being driven by technological advancements in protein-based drug development. Therapeutic proteins cannot be synthesized chemically, they need to be produced by genetic engineering and recombinant DNA technology in living cells or organisms. Protein-engineering platform technologies such as glycoengineering, pegylation, Fc-fusion, albumin fusion, and albumin drug conjugation help to increase the production yield, product purity, circulating half-life, targeting, and functionality of therapeutic proteins drugs. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, and recombinant human coagulation factor IX are some therapeutic proteins drugs developed using protein engineering technologies and approved by the FDA in the past five years.

Rising Prevalence Of Chronic Diseases, Including Diabetes, Fuels Growth Of Therapeutic Protein Market

The increasing prevalence of chronic diseases, such as diabetes, is expected to propel the growth of the therapeutic protein market going forward. Chronic diseases refer to ailments that last for a year or longer, impede everyday activities, require continuing medical care, or both. Diabetes is a chronic health condition in which the body doesn’t make enough insulin or doesn’t use insulin properly. In diabetes, several protein therapeutics, such as insulin and GLP-1 receptor agonists, are used to regulate blood sugar levels and manage the disease. They stimulate the release of insulin in response to elevated blood glucose levels and also reduce the production of glucagon, another hormone that raises blood sugar. For instance, in December 2021, according to the International Diabetes Federation, a US-based intergovernmental organization, diabetes affected 537 million adults (20–79 years old) in 2021, and it is predicted that the number is going to climb to 643 million people by 2030 and a total of 783 million by 2045. Therefore, the increasing prevalence of chronic diseases, such as diabetes, is driving the growth of the therapeutic protein market. Major companies operating in the therapeutic proteins market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi S.A, Bristol Myers Squibb Co., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk A/S, Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring LLC, Chugai Pharmaceutical Co. Ltd., Biogen Inc., Kyowa Kirin Co. Ltd., Oramed Pharmaceuticals Inc., Sandoz International GmbH, Hualan Biological Engineering Inc., Genentech Inc., ProBiogen AG, Diasome Pharmaceuticals Inc., Generex Biotechnology Corp., GeneScience Pharmaceuticals Co. Ltd.

Growing Number Of Biosimilar Drugs Impede Therapeutic Protein Market Growth

Increasing the number of biosimilar drugs on the global market will slow the growth of the therapeutic proteins market. The patent expiration of therapeutic proteins such as monoclonal antibodies allows biosimilars to enter the market. For instance, in October 2022, Amneal Pharmaceuticals, Inc., a US-based generics and specialty pharmaceutical company, launched ALYMSY (bevacizumab-maly) in the United States. These cost-effective treatments, similar to the original biologics, decline the revenue and sales of therapeutic proteins market.

Rising Approvals Of Monoclonal Antibody Drugs In Protein Therapeutics

Monoclonal antibody drug approvals are increasing in the protein therapeutic segment. Chronic diseases such as cancer and immunological disorders are well treated with monoclonal antibodies. Monoclonal antibodies are a dominant and well-established product class in the protein therapeutic segment, with more safety and immunogenicity than antibodies. By overcoming the problems associated with previous antibody drugs, cell-based expression systems, such as the Chinese hamster ovary (CHO) mammalian cell expression system, have increased the productivity of monoclonal antibodies. In the last five years, the FDA has approved 213 drugs, among which 44 are monoclonal antibodies. For instance, twelve monoclonal antibodies were approved by FDA for the treatment of cancer and immunological disorders.

Expanding Production Capacities With Media Systems In The Therapeutic Protein Market

Major companies operating in the therapeutic protein market are focused on introducing media systems to meet growing demand for therapeutic proteins and gain a competitive edge in the market. The media system for therapeutic proteins is a production system designed to optimize the production of therapeutic monoclonal antibodies. For instance, in July 2023, Lonza Group AG, a Switzerland-based pharmaceutical manufacturing company, launched the TheraPRO CHO (Chinese Hamster Ovary) Media System, a new cell culture platform to improve productivity and quality in therapeutic protein manufacture. The two-part, chemically specified production technique is simple to use and makes media preparation easier. It has full scalability and is supported by technical professionals with in-depth troubleshooting knowledge.

Eli Lilly And Company's Acquisition Of Protomer Technologies

Eli Lilly and Company, a US-based pharmaceutical company, paid $1 billion for Protomer Technologies Inc. in July 2021. Lilly is delighted to add protomer’s breakthrough technology to its diabetes pipeline through this acquisition, since the company’s glucose-sensing insulin program, which is based on its proprietary molecular engineering of protein sensors (MEPS) platform, is exhibiting great potential. Protomer Technologies Inc. is a US-based company that specializes in next-generation protein therapies that can detect molecular activators in the body and are currently being developed. North America was the largest region in the therapeutic proteins market in 2023. The regions covered in the therapeutic proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the therapeutic proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain The therapeutic proteins market consists of sales of antibody-based drugs, FC fusion proteins, and anticoagulants. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The therapeutic proteins market research report is one of a series of new reports from The Business Research Company that provides therapeutic proteins market statistics, including industry global market size, regional shares, competitors with a therapeutic proteins market share, detailed therapeutic proteins market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic proteins industry. The therapeutic proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Digestive Enzymes Market Definition

Digestive enzymes refer to compounds that aid in digestion by assisting with food breakdown. These proteins accelerate the chemical processes that transform food into compounds that can be absorbed by the digestive system. The salivary glands and the cells lining the stomach, pancreas, and small intestine produce (release) them. The main types of digestive enzymes are carbohydrates, protease, lipase, and other enzyme types. Lipase is a protein produced by the pancreas, a small organ located near the stomach that aids in fat digestion. The enzymes originated from animals, fungi, microbial, and plants that are used for indigestion, chronic pancreatitis, irritable bowel syndrome, and other applications. The various distribution channel includes retail stores and online stores.

Digestive Enzymes Market Segmentation

The digestive enzymes market covered in this report is segmented – 1) By Enzyme Type: Carbohydrates, Protease, Lipase, Other Enzyme Types 2) By Origin: Animal, Fungi, Microbial, Plant 3) By Application: Indigestion, Chronic Pancreatitis, Irritable Bowel Syndrome, Other Applications 4) By Distribution Channel: Retail Stores, Online Stores

Oncology Biosimilars Market Definition And Segments

Oncology biosimilars refer to biologically similar drugs or medications that are physiologically comparable to biological cancer treatments. Infection risk is increased by decreased white blood cell counts, which can be treated as a side effect of cancer therapy. The main drug types of oncology biosimilars are monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The types of cancer treated include breast cancer, colorectal cancer, blood cancer, neutropenia cancer, and non-small cell lung cancer, and the various distribution channels involved are hospital pharmacies, retail pharmacies, and online pharmacies. The oncology biosimilars market covered in this report is segmented – 1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF) 2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types 3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy The oncology biosimilars market size has grown exponentially in recent years. It will grow from $6.9 billion in 2023 to $8.85 billion in 2024 at a compound annual growth rate (CAGR) of 28.3%. The growth in the historic period can be attributed to rising prevalence of cancer, patent expirations of biologic cancer drugs, government support for biosimilars, growing investments in biosimilar development and manufacturing, expanding geographical reach of biosimilars. The oncology biosimilars market size is expected to see exponentially grown in the next few years. It will grow to $16.48 billion in 2028 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to expanding oncology biosimilar portfolio, patient-centric care, healthcare cost containment, targeted therapies, expanding pipeline. Major trends in the forecast period include biobetters, oncology biosimilar combinations, supportive care biosimilars, real-world evidence.

Patent Expirations Drive New Oncology Biosimilars

The expiration of the patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms that induce the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offer the same effectiveness as biologics at a reduced cost. According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for the oncology biosimilars market.

Government-Led Cancer Reduction Initiatives Catalysts For Oncology Biosimilars Market Growth

Government initiatives for reducing cancer are expected to propel the growth of the oncology biosimilars market going forward. Government initiatives refer to actions, policies, or programs introduced and implemented by government authorities at various levels (local, regional, national, or even international) to address specific issues or achieve particular objectives. These initiatives to reduce cancer can create a favorable environment for the development and adoption of oncology biosimilars by providing financial support, regulatory assistance, and public awareness. For instance, in 2022, according to the National Cancer Institute, a US-based government agency, President Biden announced a reignition of the Cancer Moonshot, highlighting new goals to reduce the cancer death rate by half within 25 years and improve the lives of people with cancer and cancer survivors. The Cancer Moonshot is marshaling resources across the federal government to speed progress in cancer research and lead to improved cancer prevention. Therefore, government initiatives for reducing cancer drive the oncology biosimilars market. Major companies operating in the oncology biosimilars market include Biocon Biologics Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Baxter International Inc., Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Shanghai Henlius Biotech, Viatris Inc., Catalent Inc., Patheon, Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech

Unlocking The Potential Addressing The Awareness Gap Among Healthcare Professionals For Oncology Biosimilars

The lack of awareness of biosimilars among primary care physicians (PCPs) and specialists limits the growth of the oncology biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, a lack of detailed awareness of the biosimilars amongst the prescribers reduces the prescriptions of biosimilars affecting the biosimilar market. For instance, as reported by the Health Research Institute of PricewaterhouseCoopers, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns including the safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the oncology biosimilars market.

Fostering Innovation Through Research And Development For Oncology Biosimilars

Pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting the growth potential of the rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For instance, in February 2021, Coherus and Junshi Biosciences announced a collaboration in which Coherus would in-license toripalimab, an anti-PD-1 antibody in the US and Canada. Coherus plans to build a leading immuno-oncology franchise using cash from its commercial biosimilar business.

Increasing Focus On Investments To Support The Battle Of Cancer

Major companies operating in oncology biosimilars are investing in cancer drugs to support the battle of cancer. Company investments in oncology biosimilars emerge as a pivotal bridge between quality cancer care and sustainable healthcare solutions. For instance, in March 2023, Pfizer, a US-based pharmaceutical company merged with Seagen and invested $43 billion to battle cancer. This enhances Pfizer’s presence in the field of oncology and battle against cancer, a leading cause of death worldwide. North America was the largest region in the global oncology biosimilars market in 2023. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The oncology biosimilars market consists of sales of Ogivri, Herzuma, Ontruzant, and Trazimera. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The oncology biosimilars market research report is one of a series of new reports from The Business Research Company that provides oncology biosimilars market statistics, including oncology biosimilars industry global market size, regional shares, competitors with an oncology biosimilars market share, detailed oncology biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. This oncology biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Interferons Market Definition And Segments

Interferons refer to a natural substance that supports the body's immune system in the battle against illness, including cancer. White blood cells and other cells in the body produce interferons, but they can also be produced in a lab for use in treating various disorders. The main types of interferons are interferon alpha, interferon beta, and interferon-gamma. Interferon alpha is a cytokine generated by the innate immune system in response to environmental exposures, including viral infections. The products are distributed by hospital pharmacies, online pharmacies, retail pharmacies, and others and are used for the treatment of hepatitis B, hepatitis C, melanoma, leukemia, multiple sclerosis, and renal cell carcinoma. The interferons market covered in this report is segmented – 1) By Type: Interferon Alpha, Interferon Beta, Interferon Gamma 2) By Application: Hepatitis B, Hepatitis C, Melanoma, Leukemia, Multiple Sclerosis, Renal Cell Carcinoma 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels The interferon market size has grown steadily in recent years. It will grow from $9.17 billion in 2023 to $9.54 billion in 2024 at a compound annual growth rate (CAGR) of 4.0%. The growth in the historic period can be attributed to viral infections, antiviral therapies, cancer treatment, and autoimmune diseases. The interferons market size is expected to see steadily grown in the next few years. It will grow to $11.98 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to immunotherapy advancements, precision medicine, viral outbreak preparedness, drug combinations, and gene therapy. Major trends in the forecast period include expanding applications, biopharmaceutical innovation, interferon combinations, and personalized medicine.

Elevated Incidence Of Cancer Propels Growth In The Interferon Market

The rise in cancer is expected to boost the growth of the interferon market going forward. Cancer is a group of diseases characterized by the development of abnormal cells that divide uncontrollably and can spread to other parts of the body. Interferons are used in the treatment of various types of cancer, including melanoma, Kaposi's sarcoma, and certain leukemias. They are often included in combination therapies, helping to boost the body's immune response against cancer cells. For instance, in January 2022, according to a report published by the American Cancer Society, a US-based health organization, in the US, 609,360 cancer deaths and 1.9 million new cancer cases are anticipated in 2022. There are expected to be 10,470 pediatric cancer cases in 2022. Additionally, 5,480 teenagers are anticipated to have cancer diagnoses in 2022. Therefore, the rise in cancer is driving the growth of the interferon market.

Rapid Growth Of The Interferon Drugs Market Driven By Chronic Diseases

The global interferon drugs market is projected to grow at a rapid pace in the next few years due to the increasing incidence of chronic diseases such as hepatitis B, hepatitis C, cancer, and multiple sclerosis, the use of interferons in combinational therapies, and the advent of novel drug delivery systems. Various types of interferon (IFN) have been used to treat these diseases and an important development in treating some of these diseases was the recognition that the clinical effects of the IFN drug could be greatly enhanced by combining it with other drugs. For instance, IFN-a (interferon-alpha) in combination with ribavirin and polyethylene glycol molecule has shown significant improvements in virologic response without any adverse effects. However, due to the poor stability of interferon-alpha in the gastrointestinal tract, only parenteral administration ensures bioavailability, which is associated with severe side effects. Studies showed that nanoencapsulation of IFN-a within nanoparticles would improve the oral bioavailability of this drug. The use of interferons in combinational therapies and the advent of novel drug delivery systems are therefore expected to drive the market for interferons. Interferons are also being tested for their use in the treatment of COVID-19. Major companies operating in the interferons market include Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Biogen Inc., Bayer AG, Zydus Cadila Health Care Limited, Novartis AG, Pfizer Inc., Biosidus S.A., Nanogen Biopharmaceutical Co. Ltd., Amega Biotech Inc., Rhein Minapharm Biogenetics S.A.E., PROBIOMED S.A. de C.V., Schering-Plough Corporation, 3SBio Inc., AbbVie Inc., Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline PLC, Johnson & Johnson, Novo Nordisk A/S, Sanofi S.A., Shire PLC, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Biocad, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hetero Drugs Limited

Challenges In Interferon Development

The development of interferons involves high R&D costs. The development of interferons is costlier than developing small molecules which are chemically synthesized, involve high operating costs, and require a greater capital investment. This is because biological drugs are more complex than small molecules and involve complex manufacturing processes. Additionally, manufacturers have to submit more data to demonstrate the efficacy and safety of these biologics in pre-clinical and clinical studies for successful registration. This makes the registration of biologics a costly and time-consuming process which is restraining the market growth. Due to the high R&D costs, and lengthy testing and manufacturing process, the marketed drugs would be priced much higher than the actual manufacturing costs, and this factor is likely to challenge the market growth.

Rising Adoption Of Interferon Biosimilars

Biologics therapy is expensive and it places a substantial financial burden on the healthcare system. The increasing prevalence of diseases such as hepatitis, MS, and cancers in the world presented an opportunity to evaluate the clinical applications of biosimilars and has stimulated some of the local pharmaceutical companies to produce interferon biosimilar medications to compete (or replace) the original expensive brands. IFNs were initially investigated for their potential as antivirals, however, they are now commonly used in anti-HBV (hepatitis B virus) and anti-HCV (hepatitis C virus) therapy. The therapeutic potential of interferon biosimilars for hepatitis and cancer, coupled with the ongoing studies on interferon biosimilars to have prophylactic or therapeutic effectiveness in SARS (severe acute respiratory syndrome), influenza, or another virus pandemic, is contributing to the increasing adoption of interferon biosimilars over expensive biologics.

Product Innovations In The Interferons Market

Major companies operating in the interferons market are developing new products such as Ropeginterferon alfa-2b-njft injections to meet larger customer bases, more sales, and increased revenue. Ropeginterferon alfa-2b-njft injection refers to a medication used in the treatment of certain medical conditions, particularly chronic diseases, and viral infections. For instance, in November 2021, PharmaEssentia Corporation, a Taiwan-based biotechnology company, announced the FDA approval for the Besremi (ropeginterferon alfa-2b-njft) injection. Besremi marks a significant milestone as the first FDA-approved medication for polycythemia vera that is suitable for patients, regardless of their treatment history. It is also the inaugural interferon therapy to receive FDA approval for the treatment of polycythemia vera. Besremi is thought to function by binding to specific receptors within the body, initiating a series of events that lead to a reduction in blood cell production in the bone marrow. This long-acting medication is administered through subcutaneous injections, with patients typically receiving it once every two weeks.

Bayer Collaborated With Curadev Pvt. Ltd.

Bayer and Curadev Pvt. Ltd., a drug discovery company based in India, have announced a research collaboration and license agreement for Curadev’s Stimulator of Interferon Genes (STING) antagonist program. The objective of this collaboration between Bayer and Curadev is to discover new drug candidates for the treatment of lung diseases, cardiovascular diseases, and other inflammatory diseases. STING antagonists have huge potential for new treatments as STING is known to help activate the innate immune system in auto-inflammatory diseases. North America was the largest region in the interferons market in 2023. Middle East is expected to be the fastest-growing region in the interferons market during the forecast period. The regions covered in the interferons market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the interferons market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada The interferons market consists of sales of polypeptides, cytokine, and cell-surface receptors. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The interferons market research report is one of a series of new reports from The Business Research Company that provides interferons market statistics, including the interferons industry's global market size, regional shares, competitors with an interferons market share, detailed interferons market segments, market trends, and opportunities, and any further data you may need to thrive in the interferons industry. This interferons market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Bi-Specific MAbs Market Definition And Segments

Bi-specific MAbs or bispecific monoclonal antibodies refer to antibodies that have two binding sites and are designed to bind to two antigens that are either distinct or have two different epitopes. Monoclonal antibodies (MoAbs) do not have the clinical therapeutic effects of BsAbs, which have a wide range of applications for the treatment of different diseases as well as tumor immunotherapy. The main types of bi-specific are catumaxomab (removal), blinatumomab, duligotumab, and SAR 156597. Catumaxomab is a rat-mouse hybrid monoclonal antibody used to treat malignant ascites, a condition that occurs in people who have metastasizing cancer. The various product types including in vivo, and in vitro are used for the treatment of cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases, and others. The bispecific monoclonal antibodies are used by hospitals, research institutes, and others. The bi-specific MAbs market covered in this report is segmented – 1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab 2) By Product Type: In Vivo, In Vitro 3) By Indication: Cancer, Hemophilia A, Ophthalmic 4) By End Use: Hospitals, Research Institutes, Other End-Users The bi-specific MAbs market size has grown rapidly in recent years. It will grow from $8.81 billion in 2023 to $10.25 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to increased healthcare expenditure, increased funding, and government initiatives. The bi-specific MAbs market size is expected to see rapid growth in the next few years. It will grow to $16.9 billion in 2028 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to an increasing prevalence of cancer, an increasing aging population, and an increase in the prevalence of chronic diseases. Major trends in the forecast period include a focus on technological advancements, product innovation, a focus on artificial intelligence, investment in targeted and combination therapy, and strategic partnerships.

Impact Of Increasing Cancer Prevalence On The Bi-Specific MAbs Market

The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bispecific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered to be more effective than monoclonal antibodies (moAbs) as these target two or more tumor antigens on cells to disrupt cancer progression. For instance, in 2023, according to the Cancer Facts & Figures 2023 report published by the American Cancer Society (ACS), a US-based voluntary health organization, there will be an estimated 609,820 cancer-related deaths in the USA. Therefore, a rising number of chronic diseases, including cancer, is anticipated to propel the demand for bi-specific MAbs to treat these diseases effectively.

Government Support In Healthcare Research And Development Boosting The Bi-Specific MAbs Market

Government initiatives for research and development in healthcare are expected to propel the growth of the growth of the Bi-Specific MAbs market going forward. Government initiatives refer to specific actions, programs, policies, or projects undertaken by government authorities to address specific issues, achieve certain goals, or create positive changes in society. For Instance, in August 2023, The Biomedical Advanced Research and Development Authority (BARDA), a U.S. Department of Health and Human Services (HHS) collaborated with Regeneron Pharmaceuticals Inc., a US-based science and technology company for the development of a next-generation monoclonal antibody therapy for the prevention of SARS-CoV-2 infection as part of the U.S. Department of Health and Human Services' 'Project NextGen.' The agreement entails up to 70% of funding from the U.S. government for Regeneron's costs in clinical development activities for the monoclonal antibody therapy, with an estimated contract value of approximately $326 million. Therefore, the government initiatives for research and development in healthcare drive the Bi-Specific MAbs market. Major companies operating in the bi-specific MAbs market report are F. Hoffmann-La Roche AG, Amgen Inc., Johnson & Johnson, Innovent Biologics, Sino Biological Inc., Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, EpimAb Biotherapeutics, Merck & Co Inc., Eli Lilly Company Inc., AbbVie Inc., Bayer AG, Pfizer Inc., Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, Enteris BioPharma, BioMarin Pharmaceuticals, Parexel, Hikma Pharmaceuticals PLC, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd., Baxter International, Cipla Medpro South Africa

Growing Popularity Of Alternative Cancer Therapies Implications For The Bi-Specific MAbs Market

The availability of various alternative treatment methods for cancer is expected to limit the growth of the bispecific monoclonal antibodies market. Alternative cancer treatment therapies and methods used for the treatment of cancer including dietary treatments, acupuncture, homeopathy, and herbal remedies are gaining popularity in recent years attributed to side effects of chemotherapeutic anticancer agents. For instance, Ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many of the herbs used in Ayurveda have anti-cancer properties, for example, andrographispaniculata. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source, and developing nations are using the benefits of natural compounds for therapeutic purposes. Therefore, this affects the biologic sales and hence impacts the bi-specific MAbs market. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027, growing at a CAGR of 14% during the forecast period. The less expensive alternative medicines increase competition for the biologics market, thereby, hindering the growth of the bi-specific MAbs market shortly.

Strategic Collaborations And Partnerships Fuel Growth In The Bi-Specific MAbs Market

Companies in the bi-specific MAbs market are increasingly investing in various strategic initiatives, such as collaborations and partnerships to expand the product portfolio and geographical presence of the company. A strategic collaboration is a cooperative partnership between two or more organizations to achieve common goals or objectives. For instance, in October 2022, Gilead Sciences, a US-based biopharmaceutical company, and MacroGenics, a US-based biopharmaceutical company, entered into an exclusive collaboration to develop MGD024, a bispecific antibody targeting CD123 and CD3 using MacroGenics' DART platform, along with two other bispecific research programs. The collaboration grants Gilead an exclusive option to license MGD024, which has the potential to treat various hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is designed to minimize cytokine-release syndrome (CRS) and allow intermittent dosing, potentially leading to more patient-friendly treatment and improved clinical outcomes for individuals with AML and MDS.

Advanced Technologies Transforming The Bi-Specific MAbs Market

Major companies operating in the Bi-Specific MAbs market are introducing advanced technologies such as bispecific monoclonal antibodies to gain a competitive edge in the market. Bi-specific monoclonal Antibodies (MAbs) are a type of artificial protein that can simultaneously bind to two different types of antigens. These antibodies are designed to target specific molecules present on the surface of cells. For instance, in September 2021, Amgen, a US-based biopharmaceutical company, and Boehringer Ingelheim, a Germany-based pharmaceutical company are collaborating on a Phase II-ready project. Convincing clinicians to transition between bispecific MAbs would necessitate significant improvements in efficacy or safety. Alternative strategies, such as initiating treatment at an earlier stage, modifying the administration method, or adjusting the treatment frequency, are feasible but demand timely strategic planning from the developers. Bispecific mAb is poised not only to outperform its competitors but also to potentially encroach upon the market share of CAR-T cell therapies in the relapsed or refractory multiple myeloma sector.

Takeda's Strategic Acquisition: Expanding Bispecific Antibody Technology

In March 2021, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company acquired Maverick Therapeutics for an undisclosed amount. With this acquisition, Takeda aims at developing bispecific antibody technology and patients would benefit from the expansion of resources and experience and accelerate development of our T-cell engager platform and pipeline of innovative bispecific immunotherapies. Maverick Therapeutics is a US-based company that offers biospecific MAbs. North America was the largest region in the bi-specific MAbs market in 2023. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the bi-specific MAbs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of trifunctional antibodies, chemically linked Fabs, and bispecific T cell engagers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The bi-specific MAbs or bispecific monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides bi-specific MAbs or bispecific monoclonal antibodies market statistics, including bi-specific MAbs or bispecific monoclonal antibodies industry global market size, regional shares, competitors with a bi-specific MAbs or bispecific monoclonal antibodies market share, detailed bi-specific MAbs or bispecific monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the bi-specific MAbs or bispecific monoclonal antibodies industry. This bi-specific MAbs or bispecific monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Cell Therapy Market Definition And Segments

Cell therapy refers to the replacement or repair of damaged tissue and/or cells through the transplantation of human cells. Numerous different types of cells may be used as part of a therapy or treatment for a number of diseases and disorders with the help of new technologies, inventive products, and infinite imagination. It is a form of treatment wherein a patient receives live cells via injection, grafting, or implant in order to produce a therapeutic result. The main techniques used in cell therapy are stem cell therapy, cell vaccines, adoptive cell transfer (ACT), fibroblast cell therapy, and chondrocyte cell therapy. Stem cell treatment, also known as regenerative medicine, uses stem cells or their derivatives to stimulate the healing response of sick, defective, or wounded tissue. The different types of therapies include allogeneic therapies, and autologous therapies and are used in various applications such as oncology, cardiovascular disease (CVD), orthopedics, wound healing, and others. The cell therapy market covered in this report is segmented – 1) By Technique: Stem Cell Therapy, Cell Vaccine, Adoptive Cell Transfer (ACT), Fibroblast Cell Therapy, Chondrocyte Cell Therapy 2) By Therapy Type: Allogeneic Therapies, Autologous Therapies 3) By Application: Oncology, Cardiovascular Disease (CVD), Orthopedic, Wound Healing, Other Applications The cell therapy market size has grown rapidly in recent years. It will grow from $12.58 billion in 2023 to $14.72 billion in 2024 at a compound annual growth rate (CAGR) of 17.0%. The growth in the historic period can be attributed to early research and discoveries, regulatory milestones, clinical trials and studies, early adopters and pioneering companies, market acceptance and perception. The cell therapy market size is expected to see rapid growth in the next few years. It will grow to $25.86 billion in 2028 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to ethical and societal considerations, investment and funding trends, consumer/patient demand, healthcare infrastructure, rapid innovation cycles. Major trends in the forecast period include personalized medicine, emerging targeted treatments, gene editing technologies, stem cell research expansion, immunotherapy advancements, microenvironment manipulation.

The Soaring Prevalence Of Chronic Diseases Fuels Expansion In The Cell Therapy Market

The rising prevalence of chronic diseases aided the expansion of the cell therapy market. According to the US Centers for Disease Control and Prevention (CDC), chronic disease is a condition that lasts for one year or more, requires medical attention, limits daily activities, or both, and includes heart disease, cancer, diabetes, and Parkinson’s disease. Stem cells can benefit patients suffering from spinal cord injuries, type 1 diabetes, Parkinson’s disease (PD), heart disease, cancer, and osteoarthritis. For instance, according to the Center for Disease Control and Prevention report in 2021, due to poor nutrition and a lack of physical activity, 6 in 10 adults in the USA are suffering from a chronic disease, and 4 in 10 have two or more diseases. In December 2021, according to the International Diabetes Federation, a Belgium based health organization, about 537 million people (20–79 years old) will have diabetes. By 2030, there will be 643 million diabetics worldwide, and by 2045, there will be 783 million. Nearly one-half of all diabetics (240 million) go undiagnosed, and three out of every four diabetic adults live in low- and middle-income countries. According to the Parkinson’s Foundation, in 2021, approximately 60,000 Americans will be diagnosed with PD each year, and 10 million individuals worldwide will suffer from this disease. After Alzheimer's, it is the second most prevalent neurological disease. The growing prevalence of chronic diseases increased the demand for cell therapies and contributed to the growth of the cell therapy market.

Surge In Investment Fueling The Growth Of The Cell Therapy Market

The rising investment is expected to propel the growth of the cell therapy market going forward. Investment in cell therapy refers to the allocation of financial resources, capital, or funding to support the research, development, manufacturing, and commercialization of cell-based therapies. Investment in cell therapy is being used to support the research and development of new cell therapy products and technologies, as well as to conduct clinical trials to evaluate these products and technologies, which will boost and improve cell therapies. For instance, in February 2022, according to reports published by Cell & Gene, a US-based life sciences company, cell therapy has grown significantly, reflecting an astonishing increase from $362 million in investment in 2020 to nearly $68 billion in 2021. Therefore, rising investment is driving the growth of the cell therapy market. Major companies operating in the cell therapy market report are Celgene Corporation, JCR Pharmaceuticals Co. Ltd., Baxter Healthcare Corporation, Nipro Corp., Stempeutics Research Pvt. Ltd., Osiris Therapeutics Inc., Vericel Corporation, AlloSource, Anterogen Co. Ltd., Arteriocyte Medical Systems Inc., MediPost Co. Ltd., Pharmicell Co. Ltd., Corestem Inc., Stemedica Cell Technologies Inc., Adaptimmune Therapeutics PLC, Mesoblast Ltd., Cell Medica Ltd., Cellerant Therapeutics Inc., Kolon TissueGene Inc., Tego Science Inc., Athersys Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Forticell Bioscience Inc., Bone Therapeutics, Holostem Terapie Avanzate S.r.l, Fibrocell Science Inc., AlloCure Inc., TiGenix NV, Cells for Cells, AVROBIO Inc., Cellular Biomedicine Group Inc., Thermo Fisher Scientific Inc., Merck Co. & KGaA, Charles River Laboratories International Inc., Lonza Group Ltd., Catalent Inc.

The Challenge Of High Costs Impeding The Growth Of The Cell Therapy Industry

The high cost of cell therapy has hindered the growth of the cell therapy industry. Cell therapies have become a common choice of treatment in recent years as people look for the newest treatment options. Although there is a huge increase in demand for cell therapies, they are still very costly to try. Basic joint injections can cost around $1,000, and more specialized procedures can cost up to $100,000 depending on the condition. In the United States, the average cost of stem cell therapy in 2020 is expected to range between $4,000 and $8,000 per patient. Therefore, the high cost of cell therapy restrains the growth of the cell therapy market.

Strategic Partnerships And Acquisitions Drive Expansion In The Cell Therapy Market

Key market players are strategically partnering and collaborating to expand the company's product portfolio and geographical presence. For instance, in October 2021, Takeda, a Japan-based pharmaceutical company, acquired Gamma Delta Therapeutics, a US-based company that offers cell therapies, to speed up the development of allogeneic T cell therapies for solid tumors. Furthermore, in June 2021, Charles River Laboratories, a US-based pharmaceutical company, acquired Vigene Biosciences Inc., a US-based biotech company. With this acquisition, Charles River aims to expand its gene therapy capabilities, establish an end-to-end gene therapy solution in the US, and accelerate its long-term revenue and earnings growth potential.

Genentech's Strategic Partnership With Arsenal Biosciences Aims To Advance Next-Generation Cell Therapies For Solid Tumors

Major companies operating in the cell therapy market are adopting a strategic partnership approach to provide innovative and effective therapies to patients. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in September 2022, Genentech Inc., a US biotechnology corporation, partnered with Arsenal Biosciences, Inc., a US-based programmable cell therapy company. With this partnership, they aim to accelerate the development of next-generation cell therapy products. It could lead to the development of new and more effective cell therapies for solid tumors, which would be a major breakthrough for cancer patients. And committed to investing in new technologies and bringing new and innovative treatments to cancer patients.

Takeda's Acquisition Of GammaDelta Therapeutics Enhances Its Cell Therapy Portfolio

In October 2021, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company specializing in drug development and commercialization, acquired GammaDelta Therapeutics Limited for undisclosed amount. Through this acquisition, Takeda will acquire early-stage cell therapy programmes in addition to GammaDelta's allogeneic variable delta 1 (V1) gamma-delta T cell therapy platforms, which encompass both blood-derived and tissue-derived platforms. GammaDelta Therapeutics Limited is a UK-based biotechnology company specializing in the research and development of T-cell therapy and immunotherapy for cancer treatment. North America was the largest region in the cell therapy market in 2023. The regions covered in the cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain The cell therapy market includes revenues earned by entities by enhancing the growth of new healthy skin tissue and enhancing collagen production. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cell therapy market research report is one of a series of new reports from The Business Research Company that provides cell therapy market statistics, including cell therapy industry global market size, regional shares, competitors with a cell therapy market share, detailed cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy industry. This cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Oligonucleotide Therapy Market Definition And Segments

Oligonucleotide therapy refers to a collective term for cutting-edge molecular-targeting agents that use chemically produced oligonucleotides with single-stranded DNA (DNA) or RNA (RNA) backbones that have the potential for selectivity. Oligonucleotides are made to base-pair with a strand of DNA or RNA for the majority of applications. PCR primers are oligonucleotides' most popular application (polymerase chain reaction) The main types of oligonucleotide therapy are antisense oligonucleotides, aptamers, and others. Antisense oligonucleotides (AS ONs) are synthetic DNA oligomers that hybridize to a target RNA in a sequence-specific manner. They’ve been used to successfully limit gene expression, modify precursor messenger RNA splicing, and inactivate microRNAs. It is used in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, and others, and is implemented in hospitals, and research institutes. The oligonucleotide therapy market covered in this report is segmented – 1) By Type: Antisense Oligonucleotide, Aptamer, Other Types 2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User 3) By End User: Hospitals, Research Institutes The oligonucleotide therapy market size has grown rapidly in recent years. It will grow from $4.9 billion in 2023 to $5.61 billion in 2024 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to growth in investment in research and development, market entry of early therapies, rise of gene editing techniques, early therapeutic discoveries, rnai and antisense oligonucleotide introduction. The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $8.75 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to research and development investments, global market penetration, therapeutic area expansion, disease modification strategies, regulatory adaptations. Major trends in the forecast period include customized therapies, advancements in delivery systems, rna interference (RNAI) advancements, antisense oligonucleotide innovation, gene editing techniques integration.

Increasing Cancer Epidemic Driving Growth In The Oligonucleotide Therapy Market

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the oligonucleotide therapy market during the forecast period. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rates globally is anticipated to boost demand for the oligonucleotide therapy market over the forthcoming years.

Government-Led Healthcare Research And Development Initiatives A Boost For Oligonucleotide Therapy

Government initiatives for research and development in healthcare are expected to propel the growth of the growth of the oligonucleotide therapy market going forward. Government initiatives refer to specific actions, programs, policies, or projects undertaken by government authorities at various levels (local, regional, national, or international) to address specific issues, achieve certain goals, or create positive changes in society. Several government authorities are initiating various healthcare initiatives to support various aspects including oligonucleotide therapy. For instance, in 2022, according to the Department of Health and Social Care, a UK-based government authority, the UK government announced £260 million (US $270.65) million in funding to boost healthcare research and manufacturing. This was committed by BEIS and DHSC to support NHS-led health research into diagnostics and treatment through new privacy-preserving platforms and clinical research services, and £60 million (US $63.60 million) to help expand life sciences manufacturing in the UK. Major companies operating in the oligonucleotide therapy market report are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline PLC, Gelead Sciences Inc., BioNTech SE, Moderna Inc., Biogen Inc., Bausch + Lomb Company, Jazz Pharmaceuticals PLC, QIAGEN Company, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals lnc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Hepion Pharmaceuticals lnc., Avidity Biosciences lnc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., PCI Biotech Holdings ASA, Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Dynacure S.A., Arcturus Therapeutics Holdings Inc., Intellia Therapeutics Inc., Regeneron Pharmaceuticals Inc., Editas Medicine Inc., Evox Therapeutics Ltd., ONK Therapeutics Ltd., PepGen Ltd.

FDA Approval Challenges Impede The Oligonucleotide Therapy Market's Growth

The FDA's low number of drug approvals hampered the oligonucleotide therapy market during the forecast period. For instance, according to the National Library of Medicine, a US-based government agency, in 2022, a total of 37 new drug entities were approved, but that year registered the lowest number of drug approvals since 2016. This can be attributed to the strict standards for manufacturing and high drug efficacy standards set by the regulatory bodies for approval of this therapy, thus increasing the time required for approval and limiting the growth of the market.

Innovative Oligonucleotide Therapy Advancements Pioneering Patient-Centric Solutions

The developers and providers of the oligonucleotide therapy market are investing in research and development to remodel the design of therapy to reduce its side effects on patients. The new and innovative oligonucleotides allow for precision medicine approaches and can be designed to selectively target any gene with minimal side effects. It also helps in targeting patient-specific sequences that are causative of rare diseases. In April 2023, the FDA approved Qalsody, an antisense oligonucleotide (ASO), for the treatment of patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. Qalsody targets SOD1 mRNA to reduce the synthesis of SOD1 protein

Elevating Pediatric Care Innovative Therapies In The Oligonucleotide Therapy Market

Major companies operating in oligonucleotide therapy market are introducing innovative therapies for pediatrics to drive the revenues in the market. Elevidys is the first and only gene therapy approved by the FDA for the treatment of Duchenne muscular dystrophy (DMD). For instance, in June 2023, the FDA approved Elevidys, a gene therapy for the treatment of pediatric patients of 4 through 5 years of age with Duchenne muscular dystrophy (DMD). While not specifically an oligonucleotide therapy, this approval highlights the advancements in gene-based treatments for genetic diseases.

Fostering Precision Medicine With Vanda Pharmaceuticals And Olipass Partnership To Advance Aso Therapeutics

In September 2022, Vanda Pharmaceuticals, a US-based biopharmaceutical company and OliPass , a South Korea-based biotechnology company announced a strategic partnership to develop antisense oligonucleotide (ASO) therapeutics. The partnership aims to jointly develop a set of ASO molecules based on OliPass' proprietary modified peptide nucleic acids. The partnership leverages the respective strengths of Vanda and OliPass to support the development of ASO-based precision medicine therapeutics.. North America was the largest region in the oligonucleotide therapy market in 2023. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain The oligonucleotide therapy market consists of sales of ASOs, siRNAs, miRNAs, and DNAzymes. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The oligonucleotide therapy market research report is one of a series of new reports from The Business Research Company that provides oligonucleotide therapy market statistics, including oligonucleotide industry global market size, regional shares, competitors with an oligonucleotide market share, detailed oligonucleotide therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the oligonucleotide industry. This oligonucleotide therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.